Adaptive Biotechnologies Corp (ADPT) Stock: What Does the Chart Say Monday?

The market has been neutral on Adaptive Biotechnologies Corp (ADPT) stock recently. ADPT gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.

Adaptive Biotechnologies Corp has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on ADPT!

See Full ADPT Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ADPT Stock Today?

Adaptive Biotechnologies Corp (ADPT) stock has gained 3.7% while the S&P 500 is lower by -0.14% as of 2:42 PM on Monday, Mar 11. ADPT has risen $0.13 from the previous closing price of $3.65 on volume of 1,063,590 shares. Over the past year the S&P 500 has gained 32.70% while ADPT is lower by -54.34%. ADPT lost -$1.56 per share in the over the last 12 months. To screen for more stocks like Adaptive Biotechnologies Corp click here.

More About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers. Click Here to get the full Stock Report for Adaptive Biotechnologies Corp stock.